Literature DB >> 31597514

Prevalence of Depression and Anxiety in Parkinson Disease and Impact on Quality of Life: A Community-Based Study in Spain.

Fany Chuquilín-Arista1,2, Tania Álvarez-Avellón3, Manuel Menéndez-González4,5,6.   

Abstract

BACKGROUND: Identifying neuropsychiatric disorders is essential for prompt treatment to reduce morbidity. Among these disorders, anxiety and depression have been frequently associated with Parkinson disease (PD), particularly among elderly population.
OBJECTIVE: The objective of this study is to determine the prevalence of anxiety and depression in a series of community-based PD cases in Spain, their relationship with different clinical and sociodemographic characteristics, and quality of life.
METHODS: This is an observational, descriptive, survey-based study with 95 community-based patients with PD diagnosis at different disease stages. Anxiety and depression were assessed using the State-Trait Anxiety Inventory and the Beck Depression Inventory II, respectively. Quality of life was assessed using the Parkinson's Disease Questionnaire 39.
RESULTS: The prevalence of depression and anxiety was 32.63% and 68.42%, respectively. Concomitant depression and anxiety were observed in 31.58% of patients. Patients with longer than 10 years' PD duration had an increased risk of depression. We found a relationship between the presence of anxiety, depression, and the patient's quality of life.
CONCLUSIONS: Depression is present in one-third and anxiety in two-thirds of PD cases in community settings in Spain. Depression and anxiety have a very negative impact on quality of life in PD. Both anxiety and depression are independent from sociodemographic characteristics, patient's comorbidities, or antiparkinsonian treatments; presenting as intrinsic symptoms in PD.

Entities:  

Keywords:  Parkinson disease; anxiety; depression; quality of life

Year:  2019        PMID: 31597514     DOI: 10.1177/0891988719874130

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  12 in total

Review 1.  Efficacy and safety of pramipexole in Parkinson's disease with anxiety or depression: a meta-analysis of randomized clinical trials.

Authors:  Niu Ji; Pin Meng; Bingchao Xu; Xinyu Zhou
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

2.  Plasma neurofilament light chain levels are associated with depressive and anxiety symptoms in Parkinson's disease.

Authors:  Weifang Yin; Yongyun Zhu; Baiyuan Yang; Fang Wang; Kangfu Yin; Chuanbin Zhou; Hui Ren; Xinglong Yang
Journal:  Neurol Sci       Date:  2022-01-27       Impact factor: 3.307

3.  Predictors of anxiety in Parkinson's disease: results from a 3-year longitudinal cohort study.

Authors:  Jessie S Gibson; Joseph L Flanigan; James T Patrie; W Alex Dalrymple; Madaline B Harrison
Journal:  Neurol Sci       Date:  2022-10-11       Impact factor: 3.830

4.  Human α-synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype. Rescue by oligonucleotide therapy.

Authors:  Lluis Miquel-Rio; Diana Alarcón-Arís; María Torres-López; Valentín Cóppola-Segovia; Rubén Pavia-Collado; Verónica Paz; Esther Ruiz-Bronchal; Leticia Campa; Carme Casal; Andrés Montefeltro; Miquel Vila; Francesc Artigas; Raquel Revilla; Analia Bortolozzi
Journal:  Transl Psychiatry       Date:  2022-02-24       Impact factor: 7.989

5.  Effect of the coronavirus disease 2019 pandemic on people with Parkinson's disease: experience from a Croatian regional center.

Authors:  Mario Hero; Gloria Rožmarić; Ena Šukunda; Eliša Papić; Valentino Rački; Vladimira Vuletić
Journal:  Croat Med J       Date:  2022-02-28       Impact factor: 1.351

6.  Tele-yoga for the management of Parkinson disease: A safety and feasibility trial.

Authors:  Aurora M James-Palmer; Jean-Francois Daneault
Journal:  Digit Health       Date:  2022-08-15

7.  Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson's Disease.

Authors:  Camilla Elefante; Giulio Emilio Brancati; Silvia Bacciardi; Sonia Mazzucchi; Eleonora Del Prete; Giovanni Palermo; Daniela Frosini; Ubaldo Bonuccelli; Roberto Ceravolo; Lorenzo Lattanzi; Icro Maremmani; Giulio Perugi
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

8.  Incidence of Anxiety in Parkinson's Disease During the Coronavirus Disease (COVID-19) Pandemic.

Authors:  Mehri Salari; Alireza Zali; Farzad Ashrafi; Masoud Etemadifar; Soumya Sharma; Nastaran Hajizadeh; Helia Ashourizadeh
Journal:  Mov Disord       Date:  2020-05-21       Impact factor: 10.338

Review 9.  The Role of Alpha-Synuclein and Other Parkinson's Genes in Neurodevelopmental and Neurodegenerative Disorders.

Authors:  C Alejandra Morato Torres; Zinah Wassouf; Faria Zafar; Danuta Sastre; Tiago Fleming Outeiro; Birgitt Schüle
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

Review 10.  Immune Dysregulation in Autism Spectrum Disorder: What Do We Know about It?

Authors:  Maria de Los Angeles Robinson-Agramonte; Elena Noris García; Jarasca Fraga Guerra; Yamilé Vega Hurtado; Nicola Antonucci; Neomar Semprún-Hernández; Stephen Schultz; Dario Siniscalco
Journal:  Int J Mol Sci       Date:  2022-03-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.